Neuromuscular biomarkers are associated with sarcopenia and physical performance in chronic pancreatitis: An integrative biomarker profiling study
Pancreatology · 2026
DOI: 10.1016/j.pan.2026.07.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2026. Verfasst von Rizwan Qaisar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, 27272, United Arab Emirates; Space Medicine Research Group…. Hauptthemen laut MEDLINE: Sarcopenia, Pancreatitis, Chronic, Physical Functional Performance, Neuromuscular Junction. Die Arbeit nennt 39 Literaturangaben. Gefördert von: University of Sharjah.
Abstract (Originalsprache)
BACKGROUND: Chronic pancreatitis (CP) is associated with sarcopenia and functional decline, yet the underlying mechanisms remain underexplored. Neuromuscular junction (NMJ) degradation and neurotrophic imbalance may play key roles, but relevant studies remain scarce. METHODS: We recruited 74 healthy controls, 65 patients with early CP, and 57 patients with advanced CP for evaluation of sarcopenia, including handgrip strength (HGS), muscle mass, and gait speed. Physical performance was measured using the Short Physical Performance Battery (SPPB). Plasma C-terminal agrin fragment-22 (CAF22; a marker of NMJ degradation), brain-derived neurotrophic factor (BDNF), and markers of inflammation, oxidative stress, and nutritional status were measured. RESULTS: Sarcopenia prevalence and functional impairment increased significantly with CP severity. Plasma CAF22 showed a stepwise increase from controls to early and advanced CP, with increases of 10.2% and 24.3%, respectively. BDNF declined by 12.4% in advanced CP, while the total protein and albumin were lowest in advanced CP. CAF22 displayed robust associations with HGS, gait speed, and SPPB across all groups, with the largest effect sizes in advanced CP. BDNF exhibited positive associations with muscle function, while inflammatory, oxidative, and nutritional biomarkers exhibited weaker and stage-dependent relationships. These associations appeared to strengthen with worsening CP, suggesting that neuromuscular, inflammatory, and metabolic stressors may become more closely linked to functional decline in advanced disease. CONCLUSION: CP is associated with progressive sarcopenia along with NMJ degeneration, neurotrophic imbalance, inflammation, oxidative stress, and nutritional decline. These findings highlight the potential value of CAF22 and BDNF as biomarkers of functional impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, 27272, United Arab Emirates; Space Medicine Research Group, Research Institute of Medical and Health Sciences, University of Sha…
- Department of Gastroenterology, Rehman Medical Institute, Peshawar, 25124, Pakistan.
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, 27272, United Arab Emirates; Iron Biology Research Group, Research Institute of Medical and Health Sciences, University of Sharj…
Förderung
- University of Sharjah
Zitieren
APA
Qaisar, R., Khan, T., Ahmad, F., & Karim, A. (2026). Neuromuscular biomarkers are associated with sarcopenia and physical performance in chronic pancreatitis: An integrative biomarker profiling study. Pancreatology. https://doi.org/10.1016/j.pan.2026.07.001
Vancouver
Qaisar R, Khan T, Ahmad F, Karim A. Neuromuscular biomarkers are associated with sarcopenia and physical performance in chronic pancreatitis: An integrative biomarker profiling study. Pancreatology. 2026. doi:10.1016/j.pan.2026.07.001
BibTeX
@article{Qaisar2026,
author = {Qaisar, Rizwan and Khan, Taimur and Ahmad, Firdos and Karim, Asima},
title = {Neuromuscular biomarkers are associated with sarcopenia and physical performance in chronic pancreatitis: An integrative biomarker profiling study},
journal = {Pancreatology},
year = {2026},
doi = {10.1016/j.pan.2026.07.001}
}
EUVIMED